Pre-market: EpiCept Corporation up on drug trial news
Shares of EpiCept Corporation (Nasdaq: EPCT) are gaining on news this morning that the pharmaceutical company’s drug Azixa for the treatment of primary and secondary brain tumors was shown to be effective in clinical studies. Shares have moved up $0.11, or 5.07%, to $2.28.
Shares of wireless communication software products maker Smith Micro Software, Inc. (Nasdaq: SMSI) are down following news after Thursday’s close that the company has made available its new file-recovery software tool that allows users to recover their digital media files. Shares are down $3.37, or 17.08%, to $16.36.
Bridgewater, N.J.-based Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) is flat despite news this morning that the U.S. Food and Drug Administration has granted full approval for its meningitis drug DepoCyt. Shares are down $0.01, or 0.12%, to $8.65.
Shares of cosmetics company Physicians Formula Holdings, Inc. (Nasdaq: FACE) are trading higher on news after Thursday’s close that the Azusa, Calif.-based firm will price its secondary offering of 4,391,000 shares of its common stock at $20.75. That’s above Thursday’s closing price of $21.27. Shares are up $0.85, or 4.16%, to $21.27.
San Francisco-based Life sciences company Monogram Biosciences, Inc. (Nasdaq: MGRM) has gained ground following speculation on Thursday that pharmaceutical giant Pfizer, Inc. would receive approval for its HIV drug from U.S. regulators. Monogram Biosciences is collaborating with Pfizer and has a diagnostic test which determines which patients can receive Pfizer’s drug. Shares are up $0.18, or 9.47%, to $2.08.
Shares of Dublin, Calif.-based SuperGen, Inc. (Nasdaq: SUPG) are trading lower despite news this morning that the pharmaceutical company has signed a definitive agreement to sell the rights to its anticancer treatments mitomycin and paclitaxel to Intas Pharmaceuticals Ltd. for $1.2 million. Shares are down $0.14, or 2.06%, to $6.67.
